<DOC>
	<DOCNO>NCT01749150</DOCNO>
	<brief_summary>This Phase II , open-label , parallel-arm study evaluate safety , tolerability , pharmacokinetics antiviral activity ritonavir-boosted danoprevir combination Pegasys ( peginterferon alfa-2a ) Copegus ( ribavirin ) treatment-naïve patient Asian origin chronic hepatitis C genotype 1 . Patients receive danoprevir 125 mg plus ritonavir 100 mg fix dose tablet orally twice daily combination weekly Pegasys 180 mcg subcutaneously Copegus 1000-1200 mg orally daily divide dos . Treatment duration 12 week patient without cirrhosis 24 week patient compensate cirrhosis .</brief_summary>
	<brief_title>A Study Ritonavir-Boosted Danoprevir Combination With Pegasys ( Peginterferon Alfa-2a ) Copegus ( Ribavirin ) Patients Asian Origin With Chronic Hepatitis C Genotype 1 With Without Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Adult patient East Asian Southeast Asian origin , &gt; /= 18 year age Presence chronic genotype 1 hepatitis C infection Treatmentnaïve History presence decompensated liver disease Presence history nonhepatitis C chronic liver disease Positive hepatitis B HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>